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Abstract: TLE1 is an oncogenic transcriptional co-repressor
that exerts its repressive effects through binding of tran-
scription factors. Inhibition of this protein–protein interac-
tion represents a putative cancer target, but no small-mole-
cule inhibitors have been published for this challenging in-
terface. Herein, the structure-enabled design and synthesis
of a constrained peptide inhibitor of TLE1 is reported. The
design features the introduction of a four-carbon-atom
linker into the peptide epitope found in many TLE1 binding
partners. A concise synthetic route to a proof-of-concept
peptide, cycFWRPW, has been developed. Biophysical testing
by isothermal titration calorimetry and thermal shift assays
showed that, although the constrained peptide bound po-
tently, it had an approximately five-fold higher Kd than that
of the unconstrained peptide. The co-crystal structure sug-
gested that the reduced affinity was likely to be due to
a small shift of one side chain, relative to the otherwise well-
conserved conformation of the acyclic peptide. This work
describes a constrained peptide inhibitor that may serve as
the basis for improved inhibitors.
Introduction
Transducin-like enhancer (TLE) proteins are transcriptional co-
repressors that modulate key pathways for developmental and
oncogenic signalling, such as the Notch and Wnt pathways.
The TLE proteins do not bind directly to DNA to exert their re-
pressive effect on gene transcription; instead, they utilise their
WDR domains to bind to DNA-bound transcription factors.[1]
Given their role in pathways known to be deregulated in many
cancers, it is not surprising that members of the TLE family,
particularly TLE1, have been implicated in the development
and maintenance of malignancies. Elevated levels of TLE1 have
been observed in a growing list of tumours, including cervical,
lung and colon carcinomas, and TLE1 has been recognised as
a putative oncogene.[2] Given that TLE1 does not bind to DNA
directly, and that its repressive and potentially oncogenic role
relies on the ability of the WDR domain to bind to transcrip-
tion factors, blocking of this interaction has been suggested as
a possible treatment for cancers with elevated TLE1 activity.[3]
However, to date, no TLE inhibitors have been described in the
literature.
The crystal structures of the WDR domain of TLE1 in com-
plexes with peptides derived from two different transcription
factor binding partners have been solved; thus characterising
the binding interface in detail.[3] One of these peptides
(SMWRPW) shows relatively potent (Kd=1 mm) binding to TLE1.
As discussed in more detail below, the bioactive conformation
of this peptide is characterised by a compactly folded core
formed by the central three amino acids. This compact core
engages in extensive interactions with the WDR1 domain and
positions key amino acid side chains such that they can form
additional polar and non-polar interactions (see below).[3]
Given that this peptide binds with micromolar activity and that
detailed knowledge of its binding mode and bioactive confor-
mation are available, it represents an attractive starting point
for the discovery of TLE inhibitors. Herein, we report a peptido-
mimetic approach based on the hypothesis that the compact
conformation of this peptide can be stabilised by a hydrocar-
bon linker.
Hydrocarbon-stapled macrocyclic peptides are increasingly
being explored as drug candidates and chemical probes, par-
ticularly for challenging targets, such as protein–protein inter-
actions.[4] Introducing conformational constraint through mac-
rocyclisation has a number of benefits. It particularly reduces
the entropic penalty upon binding to the target and has been
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shown to have the potential to improve cell penetration and
metabolic stability.[5]
Designing and synthesising constrained macrocyclic pep-
tides still remains a formidable challenge.[4] Nevertheless, suc-
cessful examples have been reported, particularly for constrain-
ing and stabilising a helices, b sheets and b turns.[4]
However, in the case of TLE1, the bound SMWRPW peptide
adopts neither a typical a-helical nor a b-sheet conformation,
and constraining the peptide thus required a different strategy.
As described in more detail below, we hypothesised that con-
necting two amino acids, the side chain of the first tryptophan
and the proline—which were a critical part of the binding epi-
tope—through a hydrocarbon linker would stabilise the bioac-
tive conformation. Herein, we report the design and develop-
ment of a chemical route to this hydrocarbon-linker-constrain-
ed, proof-of-concept peptide. Furthermore, we tested the
binding affinity of the constrained and corresponding acyclic
peptides and solved the structure of the constrained peptide
bound to the WDR domain of TLE1.
Results and Discussion
Design
The crystal structure of the SMWRPW peptide bound to the
WDR domain of TLE1 was obtained by soaking apo TLE1 crys-
tals in a solution of the slightly extended SMWRPW peptide.[3]
The indole moiety of the N-terminal tryptophan (Trp5) and the
central proline (Pro3) of the bound peptide tightly pack
against each other to form the core of the binding epitope
(Figure 1). This core engages in extensive hydrophobic interac-
tions with the protein.
The compact conformation positions side chains and back-
bone moieties of the peptide such that they are ideally placed
to engage in additional polar and hydrophobic interactions.[3]
The N-terminal serine residue of the SMWRPW peptide is not
resolved, which suggests that it is disordered and does not
make any specific interactions.
Our strategy to generate a constrained macrocyclic inhibitor
is illustrated in Figure 1: we hypothesised that connecting the
Ca-atom of the proline residue and the N1 nitrogen of the N-
terminal tryptophan with a hydrocarbon linker would lock the
peptide in the bioactive conformation. We modelled various
linker lengths in MOE by introducing the linker in silico into
the bound conformation of the peptide (PDB code 2CE9) and
minimising the energy of modified peptides in the TLE binding
site. The resulting poses were visually inspected for minimal
movement of the peptide side chains and low-energy confor-
mations of the linker. These experiments, together with an
analysis of synthetic accessibility (see below), suggested an
ideal length of four carbon atoms and compound 2 (Figure 1)
as a promising synthesis target.
Retrosynthesis
Our retrosynthetic analysis is depicted in Scheme 1. We envi-
sioned synthesising the constrained hydrocarbon-stapled pep-
tide 2 from the macrocyclic intermediate 4 through addition
of the N-terminal methionine and C-terminal tryptophan
through peptide coupling chemistry. Furthermore, we hypoth-
esised that intermediate 4 could be prepared from acyclic tri-
peptide 5 through ring-closing metathesis (RCM), followed by
concomitant saturation of the double bond and removal of
the Cbz protecting group under hydrogenation conditions. To
prepare the acyclic RCM precursor 5, two unnatural amino
acids were required: substituted proline 6 and allyl substituted
tryptophan 7.
This approach offered the advantage of conducting the criti-
cal RCM in solution, whilst all polar groups, particularly the
basic arginine side chain, were fully protected. Furthermore,
cyclic intermediate 4 offered the opportunity of late-stage
modification of the C- and N-terminal amino acids.
Synthesis and characterisation
The synthesis of proline derivative 6 was described in the liter-
ature and we followed the protocols with minor modifications.
We next turned our attention to the synthesis of Cbz-protected
1-allyl-l-tryptophan 7 (Scheme 2). We decided to use the Cbz
protecting group because it was stable to basic and acidic con-
ditions and because we anticipated that it could easily be re-
moved during hydrogenation of the double bond arising from
RCM; thus making an additional step unnecessary. At the start
of this work, direct allylation of unprotected l-tryptophan by
using either a copper tetramethylethylenediamine (TMEDA)
catalyst or sodium metal had been described.[6] We tested the
copper-mediated conditions, but did not observe any conver-
sion. More recently, a team from Sanofi published the synthesis
of 1-allyl-l-tryptophan protected with the tert-butyloxycarbonyl
(Boc) group, but this work was not in the public domain when
we undertook our work.[7] We hypothesised that selective ally-
lation of unprotected tryptophan could be achieved after de-
Figure 1. Top: Chemical structures of the SMWRPW peptide 1 and the con-
strained peptide 2 (the linker is drawn in red). Bottom: Co-crystal structure
of SMWRPW bound to the WDR domain of TLE1 (pdb code 2CE9) and super-
position of the modelled binding pose of the constrained peptide with the
crystallised pose of the unconstrained peptide 1.
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protonating the carboxyl group and the NH indole with two
equivalents of a strong base, such as NaH, because under
these conditions the deprotonated indole nitrogen represent-
ed the strongest nucleophile. Pleasingly, reacting l-tryptophan
with 2.5 equivalents of NaH and one equivalent of allyl bro-
mide in DMF gave the desired mono-allylated product in 40%
yield after HPLC purification. To avoid HPLC purification of the
polar, unprotected amino acid, we decided to attempt allyl-
ation and subsequent Cbz protection with benzyl chlorofor-
mate in a one-pot procedure. Gratifyingly, this procedure gave
the desired, protected amino acid 7 in an acceptable yield of
28% over two steps.
We next prepared the tripeptide RCM precursor 5 by cou-
pling the allylated proline with protected arginine (Scheme 3)
under known conditions for this proline derivative. However,
we only isolated the cyclised side product 8. The formation of
this side product is likely to be due to steric hindrance of the
amine functionality. Gratifyingly, increasing the reaction tem-
perature and concentrations of the reactants to favour biomo-
lecular reaction led to the desired dipeptide in 48% yield.
Next, we attempted removal of the Fmoc protecting group
from dipeptide 9 (Scheme 3). However, standard conditions
with piperidine as the base gave the undesired side product
11 as a single diastereomer.
Repeating the reaction with one equivalent of piperidine
and at a lower temperature (0 8C) resulted in a mixture of the
unprotected dipeptide and side product. Unfortunately, all at-
tempts to isolate the unprotected dipeptide and to remove pi-
peridine resulted in complete conversion to the diketopipera-
zine 11 side product. To solve this conundrum, we reasoned
that protonation after Fmoc deprotection would lower the nu-
cleophilicity of the free amino group sufficiently to prevent
cyclisation; thus allowing isolation by evaporation of the sol-
vent. Furthermore, we tested alternative bases, particularly
Scheme 1. Retrosynthesis of constrained peptide 2. Cbz=carboxybenzyl.
Scheme 2. Synthesis of N-allyl-Trp 7. DIPEA=N,N-diisopropylethylamine, HOBT=hydroxybenzotriazole.
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bases that were not likely to affect the subsequent peptide
coupling step. This approach indeed proved successful and
compound HCl-10 was obtained as a single stereoisomer
through clean Fmoc deprotection in EtOH by using one equiv-
alent of NaOEt as a base. Subsequent protonation of the
amine and residual traces of NaOEt through the addition of
a solution of HCl in MeOH thwarted formation of the side
product upon solvent evaporation (Scheme 3). Coupling of the
crude product with the HATU derivative of the allyl-substituted
tryptophan 7 and DIPEA as a base yielded the metathesis pre-
cursor 5 in 70% overall yield.
To our delight, the pivotal RCM proceeded readily by using
the Grubbs second-generation catalyst[8] in the presence of
1,4-benzoquinone[9] to yield the desired product 12 in 83%
yield as a 9:1 mixture of trans and cis isomers (Scheme 4).
We next investigated concomitant reduction of the double
bond and removal of the Cbz group by hydrogenation
(Scheme 4). Commonly used conditions, such as 10% palladi-
um on carbon and hydrogen at atmospheric pressure, left the
starting material intact. Elevated temperature, addition of acid
or increase of catalyst loading did not significantly improve
turnover. We next investigated other catalysts and found that
the Pearlman catalyst both reduced the double bond and re-
moved the Cbz protecting group. Complete conversion re-
quired one equivalent of Pd(OH)2/C and the addition of two
equivalents of HCl, but resulted in a yield of 76% of the re-
duced and deprotected intermediate being isolated.
With intermediate 4 in hand, we next performed coupling to
Boc-protected methionine. Although this coupling proceeded
readily, we reproducibly observed a +16 Da increase in molec-
ular weight after isolation and purification. We attributed this
increase to oxidation of methionine to the corresponding sulf-
oxide derivative 14 (Scheme 5). This oxidation has precedent
in the literature; however, the degree and rapidness of the re-
action is surprising, given that methionine is frequently incor-
porated into peptides.
As we discuss in more detail below, this methionine residue
can be replaced in the acyclic peptide by phenylalanine
without loss of activity. We thus focused our attention on the
phenylalanine derivative. Coupling of 4 with Boc-protected
phenylalanine proceeded in 68% yield after purification
(Scheme 5).
To complete the synthesis, we hydrolysed the ester by using
LiOH in methanol (86% yield) and added the final amino acid
by coupling this intermediate onto tryptophan bound to
a commercially available solid support (Scheme 5).
Cleavage of the solid support of 17 and concomitant remov-
al of the remaining two protecting groups provided the de-
sired macrocyclic peptide 18 in 10% yield over three steps
(Scheme 5).
Despite initial challenges, our synthetic approach enabled us
to access 14 mg of the desired, constrained peptide. Some of
the optimised steps, for example, the one-pot alkylation and
protection of tryptophan, as well as the convenient and mild
Scheme 3. Optimised reaction conditions for the synthesis of arginine-containing tripeptide 5. HATU=1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-
b]pyridinium 3-oxid hexafluorophosphate, Fmoc= fluorenylmethyloxycarbonyl chloride.
Scheme 4. RCM of 5, followed by removal of Cbz and double-bond hydrogenation.
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deprotection of the Fmoc group in solution, may be useful for
the synthesis of other constrained peptides.
We next investigated the binding of this macrocycle, as well
as acyclic MWRPW and FWRPW peptides, to TLE1. We used
two orthogonal binding assays, the thermal shift assay[10] and
isothermal titration calorimetry (ITC),[11] to test binding of 18
and the linear peptides to the TLE1 WD40 domain (TLE1 resi-
dues 443–770). The thermal shift data for the three peptides
are shown in Figure 2 and Table 1.
All three peptides showed significant thermal shifts that
were indicative of binding to the protein. Interestingly, the
MWRPW peptide, which is derived from the sequence of TLE1
binding partners, shows the smallest thermal increase. The
mutant FWRPW peptide causes a significantly larger thermal
shift (9.4 versus 6.3 8C). The cyclic peptide cycFWRPW (18) at
100 mm shows a thermal shift comparable to that of the corre-
sponding acyclic peptide (Table 1). However, the thermal shift
decreases when the concentration is further increased from
100 to 200 mm. This decrease is likely to be due to precipitation
of the peptide at higher concentrations. Our thermal shift data
thus suggested that all three peptides bound to TLE1.
To confirm these findings and to explore the enthalpic and
entropic contributions to binding of the linear and constrained
peptides, we performed ITC experiments. Given conformational
restriction, one might expect the constrained peptide to show
a smaller entropic penalty upon binding. However, all three
peptides showed potent binding driven by strong enthalpy
contributions.
Scheme 5. Synthesis of the final constrained peptide 18. NMP=N-methyl-2-pyrrolidone, TFA= trifluoroacetic acid, TIS= triisopropylsilane.
Figure 2. DTm plot of peptide–hTLE1 443–770 interactions in thermal shift
experiments. All measurements were carried out in triplicate and the points
are reported as mean+ standard deviation (SD). The values of DTm at the
top concentrations are also reported Table 1.
Table 1. Thermal shifts at peptide concentrations of 100 and 200 mm.
Peptide DTm [8C]
ligand 100 mm 200 mm
MWRPW 6.3 6.9
cycFWRPW (18) 8.4 7.5
FWRPW 9.4 10.1
Chem. Eur. J. 2017, 23, 9577 – 9584 www.chemeurj.org T 2017 The Authors. Published by Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim9581
Full Paper
Interestingly, for each peptide we observed a biphasic curve.
This was initially more pronounced for FWRPW and 18, but
also recognisable for the MWRPW peptide (see Figure S1 in the
Supporting Information). We repeated the MWRPW titration at
slightly higher protein and peptide concentrations to achieve
a higher enthalpy signal, and therefore, better resolution of
the titration event. Under these conditions, we also observed
a clear biphasic curve (Figure 3). The biphasic curves are indi-
cative of two binding events and we calculated the thermody-
namic data for both (Table 2).
The first phase of the curves corresponded to a molar ratio
of approximately 0.2 (that is, 20% of the protein is bound) and
the second phase corresponded to an approximate molar ratio
of 0.8; thus, the overall curve reached saturation at a molar
ratio close to 1. This suggested that only one binding site per
molecule of protein was occupied by the ligand. A possible ex-
planation for the biphasic curve is that in the binding experi-
ment the protein exists in two conformations which do not
rapidly interconvert and show different binding affinities for
the peptides. The observation that the molar ratios for the two
parts of the biphasic curve correspond to different peptides is
in agreement with this hypothesis.
In the following paragraph, we focus the discussion of the
ITC results on the second binding event (Kd2, DH2 and @TDS2)
for three reasons. The second binding event covers binding to
the large majority of the protein (&80%); the Kd values are in
agreement with published values; and, finally, due to the ex-
perimental set up, the relative errors are smaller. However, we
include data for the first binding event (Kd1, DH1 and @TDS1)
and they broadly follow the same trend.
The rank order based on the ITC Kd values (Kd2) confirms the
rank order from the thermal shift assay described above. The
acyclic FWRPW peptide shows the highest affinity with a Kd of
79 nm. It thus shows almost 10-fold more potent binding than
the peptide representing the original MWRPW sequence from
the TLE1 binding partners. The Kd2 value for cyclic peptide 18
is 522 nm and thus less potent than the corresponding acyclic
peptide, which suggests that introduction of the hydrocarbon
linker leads to a small loss of activity. Interestingly, binding of
18 is accompanied by a reduced loss of entropy compared
with the acyclic peptide, which is in agreement with the hy-
pothesis that the introduction of a constraint reduces the en-
tropic penalty (albeit that this reduced entropic loss is over-
compensated for by a larger enthalpic loss, leading to a higher
Kd compared with that of the acyclic FWRPW peptide).
To be able to interpret these thermodynamic data in light of
the binding modes, we set out to determine the crystal struc-
ture of the cyclic peptide 18. Briefly, we grew apo crystals of
the TLE1 WD40 domain by using slightly modified previously
published conditions[3] and succeeded in solving the structure
of cyclic peptide 18 bound to TLE1 to 2.18 a resolution by
soaking with a 2.5 mm solution of 18. The asymmetric unit
contained two TLE1 monomers and the electron density was
evident in both binding sites. However, the quality of the elec-
Figure 3. Top: ITC measurements of peptide–TLE1 binding interactions. Data fitting to a two-site independent binding model are shown; integrated heats are
shown in the inset. Bottom: Histograms showing DG, DH, and @TDS. The thermodynamic values are also presented in Table 1. a) MWRPW–TLE1 binding,
n=1. Experiment performed with TLE1 (40 mm) and MWRPW peptide (420 mm). b) FWRPW–TLE1 binding, n=2. Experiment performed with TLE1 (30 mm),
FWRPW peptide (240 mm), and then repeated with TLE1 (24 mm), FWRPW peptide (180 mm). Histograms represent averaged values; error bars denote SD.
c) 18–TLE1 binding, n=2. Experiment performed with TLE1 (30 mm), 18 (200 mm) and then repeated with TLE1 (30 mm), 18 (180 mm). Histograms represent
averaged values; error bars denote SD.
Table 2. The Kd and thermodynamic values determined by ITC for all peptide–TLE1 binding experiments.
N1 Kd1 [nm] DH1 [kcalmol
@1] @TDS1 [kcalmol@1] N2 Kd2 [nm] DH2 [kcalmol@1] @TDS2 [kcalmol@1]
MWRPW 0.24:0.001 3.5:1.9 @12.8:0.2 1.3 0.6:0.004 772:7.1 @11.1:0.11 2.72
FWRPW 0.18:0.002 8.6:3.9 @20.5:3.7 9.2:3.8 0.7:0.004 79.4:24.6 @14.6:0 4.6:0.2
18 0.18:0.01 24.7:24.2 @16.9:0 6.4:0.6 0.8:0.01 522:39.6 @11.8:1.8 3.2:1.7
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tron density differed in the two independent TLE1 monomers.
Chain A showed strong ligand density and allowed us to
model cyclic peptide 18 with full occupancy. The ligand densi-
ty in chain B was weaker and refined at a lower occupancy
(0.83). Therefore, we focus the discussion on the peptide
bound to chain A.
Figure 4 depicts the constrained peptide bound to TLE1 and
an overlay with the published structure of our acyclic design
template, SMWRPW (pdb code 2CE9).
Overall, the binding mode of the constrained peptide is
almost identical to that of the published acyclic peptide-
bound structure. The overall root-mean-square deviation
(RMSD) between the two structures is 0.55 a. The N-terminal
phenylalanine side chain of the constrained peptide occupies
a similar position to that of the methionine side chain, with
the aromatic side chain efficiently packing against the hydro-
phobic part of Glu 550; this potentially explains the slightly
higher affinity of acyclic FWRPW, compared with that of the
MWRPW peptide. The most significant difference between the
cyclic peptide conformation and the bound SMRWPW confor-
mation is the linker, which appears to cause a slight change in
position of the N-terminal tryptophan and could go some way
to explain the lower affinity of 18 compared with that of the
linear FWRPW peptide. This slight movement may create an
unfavourable, modestly repulsive, interaction that outweighs
the gain achieved through constraining the peptide. The ob-
servation that our cyclic peptide shows a higher Kd value, de-
spite replicating the bioactive conformation very accurately,
underscores the challenge of designing constrained peptides.
Minor differences that are outside the predictive power of cur-
rent structure-based design tools, even if high-resolution crys-
tal structures are available, can have a significant effect on bio-
activity.
Conclusion
We developed a concise synthetic route to a constrained
proof-of-concept peptide 18. Biophysical analysis by ITC and
thermal shift assays and X-ray crystallography confirmed that
the constrained peptide bound to the WD40 domain of TLE1.
Furthermore, the observation that the constrained peptide
shows binding thermodynamics that are entropically favoured,
relative to the acyclic FWRPW peptide, is in agreement with
the hypothesis that rigidifying the peptide lowered the entrop-
ic penalty upon binding to the target. However, the constrain-
ed peptide also showed an approximately six-fold lower affini-
ty than that of the acyclic peptide. The crystal structure of the
constrained peptide bound to TLE1 suggests that the linker
causes some strain in the molecule that may, at least partially,
explain the lower affinity. These observations underscore the
known challenge of designing constrained peptides. Our con-
strained peptide replicated the bioactive conformation very
well with an RMSD of 0.55 a and yet a slight deviation caused
a sufficient penalty to compensate for the gain achieved by in-
troducing the constraint.
Experimental Section
Experimental and characterisation details for all new compounds,
computational data, ITC data, assays data, crystallographic data,
and NMR spectra are provided in the Supporting Information.
Accession codes
Atomic coordinates and structure factors for the crystal structure
of TLE1 with constrained peptide 18 can be accessed by using
PDB code 5MWJ.
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